BlackRock Inc. - UROGEN PHARMA LTD ownership

UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 82 filers reported holding UROGEN PHARMA LTD in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
BlackRock Inc. ownership history of UROGEN PHARMA LTD
ValueSharesWeighting
Q3 2023$16,779,035
+47.7%
1,197,647
+9.1%
0.00%
Q2 2023$11,363,431
+332.2%
1,097,916
+285.9%
0.00%
Q1 2023$2,629,140
-15.1%
284,539
-18.5%
0.00%
Q4 2022$3,098,025
+8.0%
349,270
+1.3%
0.00%
Q3 2022$2,868,000
+2.9%
344,778
+1.3%
0.00%
Q2 2022$2,788,000
-81.2%
340,412
-80.0%
0.00%
Q1 2022$14,816,000
-9.8%
1,700,776
-1.6%
0.00%
Q4 2021$16,434,000
-42.9%
1,728,094
+0.9%
0.00%
-100.0%
Q3 2021$28,800,000
+9.2%
1,712,223
-0.9%
0.00%0.0%
Q2 2021$26,372,000
-19.0%
1,727,039
+3.4%
0.00%0.0%
Q1 2021$32,544,000
+18.1%
1,670,605
+9.2%
0.00%0.0%
Q4 2020$27,561,000
-3.8%
1,529,491
+3.0%
0.00%0.0%
Q3 2020$28,657,000
-25.2%
1,485,601
+1.4%
0.00%
-50.0%
Q2 2020$38,288,000
+53.6%
1,465,805
+4.9%
0.00%
+100.0%
Q1 2020$24,922,000
-45.6%
1,396,976
+1.8%
0.00%
-50.0%
Q4 2019$45,811,000
+37.8%
1,372,863
-1.6%
0.00%
+100.0%
Q3 2019$33,242,000
-30.9%
1,394,930
+4.2%
0.00%
-50.0%
Q2 2019$48,107,000
+208.2%
1,338,553
+216.8%
0.00%
+100.0%
Q1 2019$15,610,000
+20.8%
422,583
+40.8%
0.00%0.0%
Q4 2018$12,919,000
+166.5%
300,029
+192.4%
0.00%
Q3 2018$4,847,000
+8.5%
102,619
+14.3%
0.00%
Q2 2018$4,468,00089,7900.00%
Other shareholders
UROGEN PHARMA LTD shareholders Q4 2020
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 2,620,545$36,713,8356.69%
Wildcat Capital Management, LLC 495,606$6,943,4402.79%
SILVERARC CAPITAL MANAGEMENT, LLC 508,883$7,129,4512.16%
Opaleye Management Inc. 320,000$4,483,2001.46%
AlphaCentric Advisors LLC 165,000$2,311,6501.31%
Soleus Capital Management, L.P. 372,000$5,211,7200.48%
EAM Investors, LLC 170,523$2,389,0270.46%
RA Capital Management 1,483,697$20,786,5950.41%
Parkman Healthcare Partners LLC 145,311$2,035,8070.37%
MENORA MIVTACHIM HOLDINGS LTD. 2,303,031$32,265,4640.29%
View complete list of UROGEN PHARMA LTD shareholders